Drug lookup | Fillwise

CLODRONATE DISODIUM

1 Limited Use · 1 not a benefit

Other products in the same Health Canada class (M05B, M05BA) — coverage varies; not interchangeable

Alendronate (Fosamax): general benefit, Not a benefit
Risedronate (Actonel DR): general benefit, Not a benefit
Etidronate (Didronel): limited Use 236, 237, Not a benefit
Zoledronic acid (Aclasta): limited Use 319, 436, 523, Not a benefit
Pamidronate (Aredia): not a benefit
Alendronate + cholecalciferol (Fosavance): general benefit

1 more in the class list below

Clasteon · DIN 02245828 · 400mg · capsule

Limited Use — Reason for Use code 280, 358, 359 requiredMarketed · checked 2026-09-02

StatusLimited Use — Reason for Use code 280, 358, 359 required

Write on scriptLU code 280, 358, 359 (patient must meet the criteria below)

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 280, 358, 359

Reason for Use code 280 For the control and prophylaxis of hypercalcemia of malignancy. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 358 For the treatment of bony metastases in patients with breast cancer. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 359 For the prevention and treatment of osteolytic lesions in patients with multiple myeloma. Coverage limit: LU Authorization Period: Indefinite

1 brand, same coverage

Clasteon · DIN 02245828 Manufacturer: Knight Therapeutics Inc.; listing date 2004-10-14 Health Canada: Marketed since 2025-11-07 · brand CLASTEON · ATC M05BA02 CLODRONIC ACID · form Capsule · route Oral · ingredients CLODRONATE DISODIUM 400 MG · company Knight therapeutics inc. · schedule Prescription

Check this DIN again · Health Canada product record

Clasteon: Formulary list price $1.2083/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2083 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69944 · Verify on the e-Formulary ↗ (DIN 02245828)

Source record

DIN 02245828: Clasteon Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000212; group id 905; item number 2166; lccId 00124; manufacturer id KNT Source form: Cap; strength: 400mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.2083; ministry $1.2083 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245828 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69944

Interchangeable products

Ostac · DIN 01927078 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245828

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ostac · DIN 01927078 · 400mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-10-11 — choose a marketed DIN from the same-category list.Discontinued 2006-10-11 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-10-11 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2006-10-11 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 280, 358, 359

1 brand, same coverage

Ostac · DIN 01927078 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Cancelled post market since 2006-10-11 · brand OSTAC CAP 400MG · ATC M05BA02 CLODRONIC ACID · form Capsule · route Oral · ingredients CLODRONATE DISODIUM 400 MG · company Hoffmann-la roche limited · schedule Prescription

Check this DIN again · Health Canada product record

Ostac: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16681 · Verify on the e-Formulary ↗ (DIN 01927078)

Source record

DIN 01927078: Ostac Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 920000212; group id 905; item number 2166; lccId 00124; manufacturer id HLR Source form: Cap; strength: 400mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01927078 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16681

Interchangeable products

Clasteon · DIN 02245828 · $1.2083

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2006-10-11 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

RISEDRONATE SODIUM

· 23 products · General benefit (20), Listed, not a benefit (3) · strengths: 35mg, 5mg, 30mg, 150mg · DR Tab, Tab

ETIDRONATE DISODIUM

· 2 products · Listed, not a benefit (1), Limited Use, codes 236, 237 (1) · strengths: 200mg · Tab

ZOLEDRONIC ACID

· 12 products · Limited Use, codes 319, 436, 523 (2), Off-Formulary Interchangeable, not an ODB benefit (10) · strengths: 5mg/100mL, 4mg/5mL · Inj Sol-100mL Pk (Preservative-Free), Inj Sol-5mL Pk (Preservative-Free)

PAMIDRONATE DISODIUM

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3mg/mL, 6mg/mL, 9mg/mL · Inj Sol-10mL Vial

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

DENOSUMAB

· 8 products · Limited Use, codes 687, 688 (4), Limited Use, codes 686 (4) · strengths: 60mg/mL, 120mg/1.7mL · Inj Sol-1.0mL Pref Syr Pk (Preservative-Free), Inj Sol-Pref Syr, Inj Sol-Pref Syr (Preservative-Free), Inj Sol-Vial Pk, Inj Sol-Vial Pk (Preservative-Free)

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more

Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

INDICATIONS AND CLINICAL USE CLASTEON (clodronate disodium) is indicated: • as an adjunct in the management of osteolysis resulting from bone metastases of malignant tumors. • for the management of hypercalcemia of malignancy. Prior to treatment with clodronate disodium, renal excretion of excess calcium should be promoted by restoration and maintenance of adequate fluid balance and urine output. In responsive patients, clodronate disodium inhibits osteoclastic activity and bone resorption by decreasing the flux of calcium from the bones and thus reducing the calcium level in the blood. https://pdf.hres.ca/dpd_pm/00082361.PDF PM date: not printed or not captured Source product: CLASTEON; DIN 02245828; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Ostac: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026